Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2013, Article ID 315947, 7 pages
http://dx.doi.org/10.1155/2013/315947
Review Article

Molecular Classification of Hepatocellular Adenomas

1Inserm UMR-674, Génomique Fonctionnelle des Tumeurs Solides, IUH, 75010 Paris, France
2Labex Immuno-Oncology, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, 75005 Paris, France
3Hopital Europeen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France

Received 16 October 2012; Accepted 29 December 2012

Academic Editor: Paulette Bioulac-Sage

Copyright © 2013 Jean Charles Nault and Jessica Zucman Rossi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Cherqui, A. Rahmouni, F. Charlotte et al., “Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations,” Hepatology, vol. 22, no. 6, pp. 1674–1681, 1995. View at Google Scholar · View at Scopus
  2. D. Erdogan, O. R. C. Busch, O. M. van Delden, F. J. W. ten Kate, D. J. Gouma, and T. M. van Gulik, “Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience,” Liver International, vol. 26, no. 4, pp. 433–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Deneve, T. M. Pawlik, S. Cunningham et al., “Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy,” Annals of Surgical Oncology, vol. 16, no. 3, pp. 640–648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. H. A. Edmondson, B. Henderson, and B. Benton, “Liver cell adenomas associated with use of oral contraceptives,” The New England Journal of Medicine, vol. 294, no. 9, pp. 470–472, 1976. View at Google Scholar · View at Scopus
  5. Y. J. Chen, P. J. Chen, M. C. Lee, S. H. Yeh, M. T. Hsu, and C. H. Lin, “Chromosomal analysis of hepatic adenoma and focal nodular hyperplasia by comparative genomic hybridization,” Genes Chromosomes and Cancer, vol. 35, no. 2, pp. 138–143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Zucman-Rossi, E. Jeannot, J. T. van Nhieu et al., “Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC,” Hepatology, vol. 43, no. 3, pp. 515–524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Bioulac-Sage, J. Frédéric Blanc, S. Rebouissou, C. Balabaud, and J. Zucman-Rossi, “Genotype phenotype classification of hepatocellular adenoma,” World Journal of Gastroenterology, vol. 13, no. 19, pp. 2649–2654, 2007. View at Google Scholar · View at Scopus
  8. S. Rebouissou, P. Bioulac-Sage, and J. Zucman-Rossi, “Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma,” Journal of Hepatology, vol. 48, no. 1, pp. 163–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Laumonier, P. Bioulac-Sage, C. Laurent, J. Zucman-Rossi, C. Balabaud, and H. Trillaud, “Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification,” Hepatology, vol. 48, no. 3, pp. 808–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. M. van Aalten, J. Verheij, T. Terkivatan, R. S. Dwarkasing, R. A. De Man, and J. N. M. Ijzermans, “Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice,” Journal of Hepatology, vol. 55, no. 1, pp. 120–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Dokmak, V. Paradis, V. Vilgrain et al., “A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas,” Gastroenterology, vol. 137, no. 5, pp. 1698–1705, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Bioulac-Sage, S. Rebouissou, C. Thomas et al., “Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry,” Hepatology, vol. 46, no. 3, pp. 740–748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. C. O. Bellamy, R. S. Maxwell, S. Prost, I. A. Azodo, J. J. Powell, and J. R. Manning, “The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre,” Histopathology. In press. View at Publisher · View at Google Scholar
  14. M. Sasaki and Y. Nakanuma, “Overview of hepatocellular adenoma in Japan,” International Journal of Hepatology, vol. 2012, Article ID 648131, 6 pages, 2012. View at Publisher · View at Google Scholar
  15. M. Ronot, S. Bahrami, J. Calderaro et al., “Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification,” Hepatology, vol. 53, no. 4, pp. 1182–1191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Bluteau, E. Jeannot, P. Bioulac-Sage et al., “Bi-allelic inactivation of TCF1 in hepatic adenomas,” Nature Genetics, vol. 32, no. 2, pp. 312–315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. D. T. Odom, H. Zizlsperger, D. B. Gordon et al., “Control of pancreas and liver gene expression by HNF transcription factors,” Science, vol. 303, no. 5662, pp. 1378–1381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Yamagata, N. Oda, P. J. Kaisaki et al., “Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3),” Nature, vol. 384, no. 6608, pp. 455–458, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Bacq, E. Jacquemin, C. Balabaud et al., “Familial liver adenomatosis associated with hepatocyte nuclear factor 1α inactivation,” Gastroenterology, vol. 125, no. 5, pp. 1470–1475, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Jeannot, G. Lacape, H. Gin et al., “Double heterozygous germline HNF1A mutations in a patient with liver adenomatosis,” Diabetes Care, vol. 35, no. 5, p. e35, 2012. View at Publisher · View at Google Scholar
  21. J. F. Flejou, J. Barge, and Y. Menu, “Liver adenomatosis. An entity distinct from liver adenoma?” Gastroenterology, vol. 89, no. 5, pp. 1132–1138, 1985. View at Google Scholar · View at Scopus
  22. L. Chiche, T. Dao, E. Salamé et al., “Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature,” Annals of Surgery, vol. 231, no. 1, pp. 74–81, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Pelletier, S. Rebouissou, D. Vignjevic, P. Bioulac-Sage, and J. Zucman-Rossi, “HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines,” BMC Cancer, vol. 11, p. 427, 2011. View at Publisher · View at Google Scholar
  24. L. Pelletier, S. Rebouissou, A. Paris et al., “Loss of hepatocyte nuclear factor 1α function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis,” Hepatology, vol. 51, no. 2, pp. 557–566, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Jeannot, K. Poussin, L. Chiche et al., “Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1α-mutated hepatocellular adenoma,” Cancer Research, vol. 67, no. 6, pp. 2611–2616, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Rebouissou, S. Imbeaud, C. Balabaud et al., “HNF1α inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation,” Journal of Biological Chemistry, vol. 282, no. 19, pp. 14437–14446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Bioulac-Sage, G. Cubel, S. Taouji et al., “Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes,” The American Journal of Surgical Pathology, vol. 36, no. 11, pp. 1691–1699, 2012. View at Publisher · View at Google Scholar
  28. H. Clevers and R. Nusse, “Wnt/beta-catenin signaling and disease,” Cell, vol. 149, no. 6, pp. 1192–1205, 2012. View at Google Scholar
  29. J. C. Nault and J. Zucman-Rossi, “Genetics of hepatobiliary carcinogenesis,” Seminars in Liver Disease, vol. 31, no. 2, pp. 173–187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Micsenyi, X. Tan, T. Sneddon, J. H. Luo, G. K. Michalopoulos, and S. P. S. Monga, “β-catenin is temporally regulated during normal liver development,” Gastroenterology, vol. 126, no. 4, pp. 1134–1146, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Colnot, T. Decaens, M. Niwa-Kawakita et al., “Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 49, pp. 17216–17221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Benhamouche, T. Decaens, C. Godard et al., “Apc tumor suppressor gene is the “zonation-keeper” of mouse liver,” Developmental Cell, vol. 10, no. 6, pp. 759–770, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. W. Chen, Y. M. Jeng, S. H. Yeh, and P. J. Chen, “p53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia,” Hepatology, vol. 36, no. 4, pp. 927–935, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Bioulac-Sage, H. Laumonier, G. Couchy et al., “Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience,” Hepatology, vol. 50, no. 2, pp. 481–489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Bioulac-Sage, G. Cubel, C. Balabaud, and J. Zucman-Rossi, “Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers,” Seminars in Liver Disease, vol. 31, no. 1, pp. 91–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. van der Borght, L. Libbrecht, A. Katoonizadeh et al., “Nuclear β-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy,” Histopathology, vol. 51, no. 6, pp. 855–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Farges, N. Ferreira, S. Dokmak, J. Belghiti, P. Bedossa, and V. Paradis, “Changing trends in malignant transformation of hepatocellular adenoma,” Gut, vol. 60, no. 1, pp. 85–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Di Tommaso, G. Franchi, N. P. Young et al., “Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis,” Hepatology, vol. 45, no. 3, pp. 725–734, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. M. Lagana, M. Salomao, F. Bao, R. K. Moreira, J. H. Lefkowitch, and H. E. Remotti, “Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma,” Applied Immunohistochemistry & Molecular Morphology. In press. View at Publisher · View at Google Scholar
  40. P. Bioulac-Sage, S. Rebouissou, A. Sa Cunha et al., “Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver,” Gastroenterology, vol. 128, no. 5, pp. 1211–1218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Rebouissou, M. Amessou, G. Couchy et al., “Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours,” Nature, vol. 457, no. 7226, pp. 200–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Paradis, A. Benzekri, D. Dargére et al., “Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma,” Gastroenterology, vol. 126, no. 5, pp. 1323–1329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. D. A. Weinstein, C. N. Roy, M. D. Fleming, M. F. Loda, J. I. Wolfsdorf, and N. C. Andrews, “Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease,” Blood, vol. 100, no. 10, pp. 3776–3781, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Sa Cunha, J. F. Blanc, E. Lazaro et al., “Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management,” Gut, vol. 56, no. 2, pp. 307–309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Paradis, A. Champault, M. Ronot et al., “Telangiectatic adenoma: an entity associated with increased body mass index and inflammation,” Hepatology, vol. 46, no. 1, pp. 140–146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. S. Chun, J. Calderaro, and J. Zucman-Rossi, “Synchronous hepatocellular carcinoma and Castleman's disease: the role of the interleukin-6-signaling pathway,” Hepatology, vol. 56, no. 1, pp. 392–393, 2012. View at Google Scholar
  48. J. Sommer, T. Effenberger, E. Volpi et al., “Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling,” The Journal of Biological Chemistry, vol. 287, no. 17, pp. 13743–13751, 2012. View at Publisher · View at Google Scholar
  49. C. Pilati, M. Amessou, M. P. Bihl et al., “Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas,” Journal of Experimental Medicine, vol. 208, no. 7, pp. 1359–1366, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. J. C. Nault, M. Fabre, G. Couchy et al., “GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation,” Journal of Hepatology, vol. 56, no. 1, pp. 184–191, 2012. View at Publisher · View at Google Scholar
  51. L. S. Weinstein, J. Liu, A. Sakamoto, T. Xie, and M. Chen, “Minireview: GNAS: normal and abnormal functions,” Endocrinology, vol. 145, no. 12, pp. 5459–5464, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. L. S. Weinstein, A. Shenker, P. V. Gejman, M. J. Merino, E. Friedman, and A. M. Spiegel, “Activating mutations of the stimulatory G protein in the McCune-Albright syndrome,” The New England Journal of Medicine, vol. 325, no. 24, pp. 1688–1695, 1991. View at Google Scholar · View at Scopus
  53. M. P. Bralet, J. M. Régimbeau, P. Pineau et al., “Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 french cases,” Hepatology, vol. 32, no. 2, pp. 200–204, 2000. View at Google Scholar · View at Scopus
  54. W. M. Christopherson, E. T. Mays, and G. Barrows, “A clinicopathologic study of steroid-related liver tumors,” American Journal of Surgical Pathology, vol. 1, no. 1, pp. 31–41, 1977. View at Google Scholar · View at Scopus
  55. J. B. Rooks, H. W. Ory, and K. G. Ishak, “Epidemiology of hepatocellular adenoma. The role of oral contraceptive use,” Journal of the American Medical Association, vol. 242, no. 7, pp. 644–648, 1979. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Buehler, M. Pirovino, and A. Akovbiantz, “Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use,” Gastroenterology, vol. 82, no. 4, pp. 775–782, 1982. View at Google Scholar · View at Scopus
  57. J. B. Rooks, H. W. Ory, and K. G. Ishak, “The association between oral contraception and hepatocellular adenoma—a preliminary report,” International Journal of Gynecology and Obstetrics, vol. 15, no. 2, pp. 143–144, 1977. View at Google Scholar · View at Scopus
  58. L. A. J. Heinemann, A. Weimann, G. Gerken, C. Thiel, M. Schlaud, and T. DoMinh, “Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study,” European Journal of Contraception and Reproductive Health Care, vol. 3, no. 4, pp. 194–200, 1998. View at Google Scholar · View at Scopus
  59. P. Bioulac-Sage, S. Taouji, L. Possenti, and C. Balabaud, “Hepatocellular adenoma subtypes: the impact of overweight and obesity,” Liver International, vol. 32, no. 8, pp. 1217–1221, 2012. View at Publisher · View at Google Scholar
  60. E. Jeannot, L. Mellottee, P. Bioulac-Sage et al., “Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage,” Diabetes, vol. 59, no. 7, pp. 1836–1844, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Labrune, P. Trioche, I. Duvaltier, P. Chevalier, and M. Odièvre, “Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature,” Journal of Pediatric Gastroenterology and Nutrition, vol. 24, no. 3, pp. 276–279, 1997. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Mutel, A. Abdul-Wahed, N. Ramamonjisoa et al., “Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas,” Journal of Hepatology, vol. 54, no. 3, pp. 529–537, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. P. S. Kishnani, T. P. Chuang, D. Bali et al., “Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease,” Human Molecular Genetics, vol. 18, no. 24, pp. 4781–4790, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Svrcek, E. Jeannot, L. Arrivé et al., “Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis,” European Journal of Endocrinology, vol. 156, no. 6, pp. 617–621, 2007. View at Publisher · View at Google Scholar · View at Scopus